Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 12/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13499365 | 0.89 | HTR1A (0.50) | CHRM1DRD2KCNH2CHRM2CHRM3 | |
| SCHEMBL13499351 | 0.87 | LTA4H (0.46) | CHRM1DRD2KCNH2CHRM2CHRM3 | |
| SCHEMBL13499465 | 0.85 | MAPT (0.48) | KCNA5CHRM1DRD2KCNH2HRH1 | |
| SCHEMBL13499343 | 0.82 | LTA4H (0.46) | KCNA5CHRM1DRD2KCNH2CHRM2 | |
| SCHEMBL13499249 | 0.78 | TSHR (0.45) | MEN1KMT2A | |
| SCHEMBL13499247 | 0.74 | CYP11B2 (0.43) | MEN1HRH3KMT2A | |
| SCHEMBL13499460 | 0.73 | TMEM97 (0.45) | CHRM1DRD2KCNH2CHRM2CHRM3 | |
| SCHEMBL13499258 | 0.73 | HTR1A (0.48) | CHRM1DRD2KCNH2CHRM2CHRM3 | |
| SCHEMBL13499369 | 0.73 | HTR1A (0.48) | CHRM1DRD2KCNH2CHRM2CHRM3 | |
| SCHEMBL13499259 | 0.73 | TMEM97 (0.47) | CHRM1DRD2KCNH2CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029620-A1 | SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. | 2010-02-04 | — | — | US | disclosed |
| US-20100029620-A1 | SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029620-A1 | SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE | ADRA2C, ADRB2, CHRNA5 | KCNA5 991/4885CHRM1 46/4885DRD2 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.